Retatrutide (LY3437943)
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.
Research log summary heatmap
Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.
No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.
Anonymous side-effect patterns
Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.
No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.
Research footprint
No studies ingested yet for Retatrutide (LY3437943). The Librarian will populate this once it finds literature.
Research & intelligence feed
Studies, clinical trials, community discussions, and news.
External databases
Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.
Practical guides for Retatrutide (LY3437943)
How-to and safety articles applicable to every peptide in the library.
- Reconstitution calculatorCompute BAC water volume and syringe units for any dose.
- BAC water guideWhat bacteriostatic water is and why peptides need it.
- How to reconstitute peptidesStep-by-step mixing protocol with a worked example.
- How to inject peptidesSubcutaneous injection technique with insulin syringes.
- Where to inject peptidesSite selection, rotation, and pinch technique.
- Safety overviewSide-effect data, regulatory status, and red-flag risks.
Articles mentioning Retatrutide (LY3437943)
- Best Peptides for Fat Loss: Evidence-Based RoundupRanked roundup of peptides studied for fat loss — GLP-1 / GIP agonists, GH-axis fragments, and supporting metabolic peptides — with mechanism, evidence quality, and how to choose.weight-loss · 6 min
- Cagrilintide Explained: Amylin Agonist + CagriSema CombinationCagrilintide (AM833) is Novo Nordisk's long-acting amylin receptor agonist. Combined with Semaglutide it produces ~17–22% weight loss in Phase 3 trials with a different mechanism than GLP-1.news · 4 min
- Retatrutide Explained: The Triple-Receptor Weight-Loss Drug in Phase 3Retatrutide (LY3437943) is a GLP-1 + GIP + glucagon triple receptor agonist producing ~24% weight loss at 48 weeks in Phase 2 trials. Here's what it is, how it works, and where it stands.news · 4 min
- Semaglutide vs Tirzepatide: Mechanism, Trial Data, Which to ChooseSemaglutide vs Tirzepatide — head-to-head on mechanism (GLP-1 vs GIP+GLP-1), Phase 3 weight loss (~15% vs ~21%), side effects, cardiovascular evidence, and how to choose.comparison · 6 min
- Tirzepatide vs Retatrutide: Dual vs Triple Receptor AgonismTirzepatide is FDA-approved GIP+GLP-1 dual agonism (~21% weight loss). Retatrutide is GLP-1+GIP+glucagon triple agonism in Phase 3 (~24% Phase 2). Here's how they compare.comparison · 5 min
- Peptide Stack for Weight Loss: Defensible CombinationsWhat 'peptide stack for weight loss' actually means — the defensible combinations (CagriSema, GLP-1 + Tesamorelin, GLP-1 + healing peptides), what to avoid, and why training plus protein is the load-bearing partner.stack · 5 min
Community notes
No comments yet. Share research notes, citations, or observations below.
Community research logs (detail)
No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.
Anonymous side-effect reporting (detail)
This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.
Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.